2013 Fiscal Year Final Research Report
Biomarker exploration of VEGF inhibitor (bevacizumab) in lung cancer
| Project/Area Number |
23591750
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
KYOICHI Kaira 群馬大学, 医学(系)研究科(研究院), 講師 (40400783)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | べバシズマブ / VEGF / FDG-PET / 肺癌 |
|---|
| Research Abstract |
The level of FDG accumulation within lung cancer cells was closely associated with glucose metabolism (Glut1) and hypoxia(HIF-1). In vitro and in vivo studies, the uptake of FDG within tumor cells showed a mild change after bevacizumab monotherapy, but that markedly revealed a significant reduction after combination of paclitaxel and bevacizumab. Moreover, we had planed a clinical trial to examine the therapeutic monitoring of platinum-based regimens plus bevacizumab for patients with lung cancer. The results suggest that FDG-PET is useful tool to evaluate the treatment response after the regimens including bevacizumab in patients with lung cancer.
|
